Ensysce Biosciences, Inc. financial data

Symbol
ENSC on Nasdaq, ENSCW on OTC
Industry
Pharmaceutical Preparations
Location
7946 IVanhoe Avenue, Suite 201, La Jolla, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Leisure Acquisition Corp. (to 6/30/2021)
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 204 % +113%
Debt-to-equity 75.2 % -91.7%
Operating Margin -143 % +67.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 19.6M shares +522%
Common Stock, Shares, Outstanding 13.9M shares +384%
Entity Public Float 4.6M USD -75.5%
Common Stock, Value, Issued 1.39K USD +383%
Weighted Average Number of Shares Outstanding, Basic 9.89M shares +221%
Weighted Average Number of Shares Outstanding, Diluted 9.89M shares +221%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 4.42M USD +40.4%
Research and Development Expense 5.65M USD -52.9%
General and Administrative Expense 5.08M USD +3.09%
Operating Income (Loss) -6.31M USD +54.2%
Nonoperating Income (Expense) -1.62M USD -239%
Earnings Per Share, Basic -1.46 USD/shares +86.3%
Earnings Per Share, Diluted -1.46 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.15M USD +184%
Other Assets, Current 18K USD +125%
Assets, Current 9.09M USD +230%
Other Assets, Noncurrent 294K USD -36.2%
Assets 9.38M USD +192%
Accounts Payable, Current 1.97M USD +115%
Liabilities, Current 2.8M USD +38%
Other Liabilities, Noncurrent 26.4K USD -91.5%
Liabilities 2.8M USD +36.1%
Retained Earnings (Accumulated Deficit) -126M USD -6.72%
Stockholders' Equity Attributable to Parent 6.91M USD +365%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 6.58M USD +468%
Liabilities and Equity 9.38M USD +192%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.41M USD +5.5%
Net Cash Provided by (Used in) Financing Activities 5.69M USD +203%
Net Cash Provided by (Used in) Investing Activities 4.5K USD
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 13.9M shares +384%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 2.28M USD
Deferred Tax Assets, Valuation Allowance 38.4M USD +6.58%
Deferred Tax Assets, Gross 38.4M USD +6.56%
Depreciation 0 USD
Operating Lease, Liability, Current 2.73K USD -92.3%
Deferred Tax Assets, Operating Loss Carryforwards 28.5M USD +6.58%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 1.5M shares 0%
Unrecognized Tax Benefits 1.69M USD +18%
Operating Lease, Payments 22.7K USD +18.9%
Additional Paid in Capital 133M USD +11.2%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 5.93K USD +7.98%
Interest Expense 1.25M USD +83271%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%